Reneuron

1

Our Technologies

our_technology

Our stem cell expansion and screening technologies have enabled us to generate quality-assured stem cell lines in quantities sufficient to treat many hundreds of thousands of potential patients. Read More ....

 

Subscribe here for our Press Releases

Our Products

  our_products

We have developed stem cell therapies for serious conditions such as stroke disability where the patient populations are significant and where few if any alternative treatments exist. Read More ....

Share Price

To view detailed share price information
for ReNeuron Group plc. Click Here

Latest News

Guildford, UK, 17 April 2015: Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb
Guildford, UK, 13 April 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that it has filed an Investigational New Drug (IND) application with the US FDA to commence a Phase
Guildford, UK, 1 April 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces a number of Board and senior management changes as the Company prepares for its next phase of

ReNeuron is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Read more ....

©ReNeuron Group plc 2005-2014 All rights reserved

Privacy                Disclaimer